Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:41 PM
Ignite Modification Date:
2025-12-24 @ 5:41 PM
NCT ID:
NCT04268368
Eligibility Criteria:
Inclusion Criteria:
1. Adult patients above 18 years of age;
2. Cyto-histological diagnosis of one of the following cancers:
1. advanced melanoma;
2. metastatic or locally advanced non-small cell lung cancer;
3. advanced renal cell carcinoma;
4. metastatic or locally advanced urotelial carcinoma;
5. squamous cell carcinoma of the head and neck;
6. Hodgkin lymphoma;
7. Merkel-cell carcinoma;
3. New prescription of one of the following PD-1/PD-L1 inhibitors:
1. nivolumab
2. pembrolizumab
3. atezolizumab
4. avelumab
5. durvalumab alone or in combination therapy, following the indications of the Italian regulatory agency (AIFA).
Exclusion Criteria:
1. Patients that refuse and/or are not able to sign the Informed Consent;
2. Parents/guardians or subjects who, in the opinion of the Investigator, may be noncompliant with study schedules or procedures;
3. No contraindications to the treatment with PD-1/PD-L1 antibodies, following the indications of the Italian regulatory agency (AIFA).
Subjects that do not meet all of the enrollment criteria may not be enrolled.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04268368
Study Brief:
Protocol Section:
NCT04268368